(18)^F-FMISO乏氧显像剂的临床应用进展  

CLINICAL APPLICATION PROGRESS OF (18)^F-FMISO HYPOXIC IMAGING AGENT

作　　者：高艳青 王宇飞[2] 郭占林[2] GAO Yanqing;WANG Yufei;GUO Zhanlin(Inner Mongolia Medical University,Hohhot 010059 China)

机构地区：[1]内蒙古医科大学,内蒙古呼和浩特010059 [2]内蒙古医科大学附属医院胸外科,010050

出　　处：《内蒙古医科大学学报》2022年第1期88-91,96,共5页Journal of Inner Mongolia Medical University

基　　金：国家自然科学基金项目(81760528);内蒙古自然科学基金项目(2018lh8025);内蒙古自治区“草原英才”工程项目。

摘　　要：肿瘤乏氧是癌症病人预后不良的重要原因。乏氧可能是恶性肿瘤对治疗产生耐受的主要机制之一,而且乏氧会使肿瘤侵袭性增加。所以检测肿瘤细胞乏氧至关重要,它会为临床治疗和肿瘤病人的预后提供线索。目前检测乏氧的方法很多,但是应用于临床上的少之又少。其中核医学(PET/SPECT)分子显像技术在临床上应用最为广泛。乏氧显像剂能够选择性聚集在肿瘤乏氧区域,然后通过核医学(PET/SPECT)进行乏氧的显像。乏氧显像剂分为硝基咪唑类和非硝基咪唑类,临床上和基础实验研究中以前者为主。而(18)^F-FMISO是第一代硝基咪唑类乏氧显像剂,目前临床上应用广泛。这篇文章将会对(18)^F-FMISO的最新实验及临床研究进展及目前存在的问题等进行综述。Tumor hypoxia is an important reason for poor prognosis of cancer patients.Hypoxia may be one of the main mechanisms of malignant tumor tolerance to treatment,and hypoxia will increase tumor invasiveness.Therefore,it is very important to detect tumor cell hypoxia,which will provide clues for clinical treatment and the recovery of tumor patients.At present,there are many methods to detect hypoxia,but few of them are used in clinic.Among them,nuclear medicine(PET/SPECT)molecular imaging technology is most widely used in clinic.Hypoxic imaging agents can selectively gather in tumor hypoxic areas,and then conduct hypoxic imaging through nuclear medicine(PET/SPECT).Hypoxic imaging agents are divided into nitroimidazoles and non-nitroimidazoles,mainly the former in clinical and basic experimental studies.(18)^F-FMISO is the first generation nitroimidazole hypoxia imaging agent,which is widely used in clinic.This article will review the latest experimental and clinical research progress and existing problems of (18)^F-FMISO.

关 键 词：(18)^F-FMISO 乏氧 PET 分子显像技术 乏氧显像剂 

分 类 号：R173[医药卫生—妇幼卫生保健]